MSHLPertuzumab + Trastuzumab Fixed Dose Combination Injection 1,200 mg/600 mg, 600 mg/600 mg
1) Fixed-dose pertuzumab and trastuzumab subcutaneous injection in combination with chemotherapy for treating HER2-positive metastatic or locally recurrent breast cancer, in patients without prior treatment for metastatic disease. Treatment with pertuzumab should be stopped if disease progresses.
2) Fixed-dose pertuzumab and trastuzumab subcutaneous injection in combination with chemotherapy for adjuvant treatment of high-risk (with positive nodes) HER2-positive early breast cancer for a maximum duration of 1 year.
3) Fixed-dose pertuzumab and trastuzumab subcutaneous injection in combination with chemotherapy for neoadjuvant treatment of HER2-positive locally advanced, inflammatory or early stage (tumour >2 cm in diameter or node positive) breast cancer for 4 to 6 cycles. Following surgery, patients may continue with trastuzumab with or without pertuzumab for a total of 1 year of anti-HER2 treatment.